Magdi Yaqoob graduated in Medicine (with honours) and obtained his MBBS in Medicine (1982 - with distinction) from the Dow Medical College affiliated with the University of Karachi in Pakistan. Having been awarded the College Prize in 1983 for one of the ’Best Graduate Degree’, he received Scholarship for postgraduate training in the UK. After completing general professional training and obtaining MRCP from the Royal College of physicians (London), he started specialist training in renal medicine and transplantation at Liverpool University Hospital. During his training, he was awarded an MD by the Liverpool University for research into occupational renal diseases (1994). He also spent 1994-95 as a NIH-funded postdoctoral fellow in the university of Colorado, Denver, USA under the supervision of Professor R.W. Schrier investigating the mediators of tissue injury. His research received national and international recognition (i.e. ‘Trainee Investigator of the Year Award - 1995’ by the Association of American Physicians and ‘Young European Investigator of the Year Award – 1992’ by the European Renal Association).  In 1995, he was appointed as a consultant nephrologist at the Barts and the London NHS trust and has since been appointed as an  Academic and Training Director of the Renal Unit and Professor of Nephrology within Queen Mary’s College, UK. With the generous support of the Barts and the London Special Trustees, Kidney Research UK, British Heart Foundation, Roche, UK, Amgen, UK and Novartis, UK, he has published more than 100 scientific articles in peer-reviewed scientific journals, and renal chapters in several medical text books. He is a Fellow of the Royal College of Physicians London UK, a special Advisor to Royal college of Physicians on India, and Director of William Harvey Research Limited www.williamharvey.co.uk.

 

Current research interests

 

Uraemia Induced cardiovascular diseases: Studies in to the pathomechanisms of accelerated atheroclerosis and cardiomyopathy using several experimental models of Acute and Chronic renal failure. Over 1000 renal patients are being genotyped for SNPs in pro and anti-inflammatory genes to seek associations with cardiovascular, renal osteodystrophy and malnutrition morbidity in these patients.

Identification of novel therapeutic targets in the prevention of diabetic nephropathy: Use of in-vitro and in-vivo facilities and access to a large cohort of ethnically diverse diabetic patients we have identified calpain, nitrotyrosine, PARP activation and dysregulated polyamines pathways as potential new therapeutic targets.

Mediators of Ischaemia reperfusion injury: This interesting area of research is being investigated with several knock strain of mice and study of endothelial dysfunction by intravital microscopy. Calloboration Professor Thiermermann.

Intracellular signalling of erythropoiesis stimulating agents. This area of research is investigating the causes of poor response to ESA in renal patients. We have identified upregulation of SOCs as a potential mechanism of poor response to endogenous ESA in uraemic patients.

 

Key publications

 

• Dexamethasone ameliorates renal ischemia-reperfusion injury. Kumar S, Allen DA, Kieswich JE, Patel NS, Harwood S, Mazzon E, Cuzzocrea S, Raftery MJ, Thiemermann C, Yaqoob MM. J Am Soc Nephrol. 2009 Nov;20(11):2412-25.

• Bicarbonate supplementation slows progression of CKD and improves nutritional status.
  de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. J Am Soc Nephrol. 2009 Sep;20(9):2075-84.

• C3 polymorphisms and allograft outcome in renal transplantation. Varagunam M, Yaqoob MM, Döhler B, Opelz G. N Engl J Med. 2009 Feb 26;360(9):874-80.

• Ashman N, Harwood SM, Kieswich J, Allen DA, Roberts NB, Mendes-Ribeiro AC, Yaqoob MM . Albumin stimulates cell growth, l-arginine transport, and metabolism to polyamines in human proximal tubular cells. Kidney Int (2005);67(5):1878-89

• Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Thiemermann C, Yaqoob MM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol (2004);15(8):2115-24.

• Patel NS, Sharples EJ, Cuzzocrea S, Chatterjee PK, Britti D, Yaqoob MM, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int (2004);66(3):983-9.

• New DI, Chesser AM, Thuraisingham RC, Yaqoob MM. Structural remodeling of resistance arteries in uremic hypertension. Kidney Int (2004);65(5):1818-25.

• New DI, Chesser AM, Raftery MJ, Yaqoob MM. The myogenic response in uremic hypertension. Kidney Int (2003);63(2):642-6.

• Harwood SM, Allen DA, Raftery MJ, Yaqoob MM. Calpain is a mediator of myocardial injury in experimental uremia: is it activated by endogenous ouabain? Kidney Int Suppl (2003) (84):S177-80.

• Harwood SM, Allen DA, Chesser AM, New DI, Raftery MJ, Yaqoob MM. Calpain is activated in experimental uremia: is calpain a mediator of uremia-induced myocardial injury? Kidney Int (2003);63(3):866-77.

• Allen DA, Harwood S, Varagunam M, Raftery MJ, Yaqoob MM. High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. Faseb J (2003);17(8):908-10.

 

 

Search for more publications by Magdi Yaqoob

 

<< Return to staff list